It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The evolutionary trajectories of early lung adenocarcinoma (LUAD) have not been fully elucidated. We hypothesize that genomic analysis between pre-invasive and invasive components will facilitate the description of LUAD evolutionary patterns. We micro-dissect malignant pulmonary nodules (MPNs) into paired pre-invasive and invasive components for panel-genomic sequencing and recognize three evolutionary trajectories. Evolutionary mode 1 (EM1) demonstrates none of the common driver events between paired components, but another two modes, EM2A and EM2B, exhibit critical private alterations restricted to pre-invasive and invasive components, respectively. When ancestral clones harbor EGFR mutations, truncal mutation abundance significantly decrease after the acquisition of invasiveness, which may be associated with the intratumoral accumulation of infiltrated B cells. Harboring EGFR mutations is critical to the selective pressure and further impacts the prognosis. Our findings extend the understanding of evolutionary trajectories during invasiveness acquisition in early LUAD.
Invasive early stage lung adenocarcinoma has a heterogeneous prognosis. Here, the authors microdissect malignant pulmonary nodules to invasive and preinvasive components and study the mutations that are common or private between the lesions, allowing them to understand the evolutionary path of the tumours.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Wang, Xiaonan 9 ; Hu, Zhibin 7 ; Christiani, David C 4
; Xu, Lin 10 ; Shen Hongbing 7 ; Yin Rong 11
1 Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Department of Thoracic Surgery, Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Nanjing, P.R. China (GRID:grid.452509.f) (ISNI:0000 0004 1764 4566)
2 Nanjing Medical University, Department of Biostatistics, Center for Global Health, School of Public Health, Nanjing, P.R. China (GRID:grid.89957.3a) (ISNI:0000 0000 9255 8984); Harvard T. H. Chan School of Public Health, Department of Environmental Health, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Harvard T. H. Chan School of Public Health, Department of Epidemiology, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Massachusetts General Hospital/Harvard Medical School, Department of Medicine, Boston, USA (GRID:grid.38142.3c)
3 Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Department of Pathology, Nanjing, P.R. China (GRID:grid.452509.f) (ISNI:0000 0004 1764 4566)
4 Harvard T. H. Chan School of Public Health, Department of Environmental Health, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Harvard T. H. Chan School of Public Health, Department of Epidemiology, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Massachusetts General Hospital/Harvard Medical School, Department of Medicine, Boston, USA (GRID:grid.38142.3c)
5 Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Department of Science and Technology, Nanjing, P.R. China (GRID:grid.452509.f) (ISNI:0000 0004 1764 4566); Jiangsu Biobank of Clinical Resources, Biobank of Lung Cancer, Nanjing, P.R. China (GRID:grid.452509.f)
6 Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Department of Thoracic Surgery, Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Nanjing, P.R. China (GRID:grid.452509.f) (ISNI:0000 0004 1764 4566); Nanjing Medical University, Department of Epidemiology and Biostatistics, International Joint Research Center on Environment and Human Health, Center for Global Health, School of Public Health, Nanjing, P.R. China (GRID:grid.89957.3a) (ISNI:0000 0000 9255 8984)
7 Nanjing Medical University, Department of Epidemiology and Biostatistics, International Joint Research Center on Environment and Human Health, Center for Global Health, School of Public Health, Nanjing, P.R. China (GRID:grid.89957.3a) (ISNI:0000 0000 9255 8984)
8 Geneplus-Beijing Institute, Beijing, P.R. China (GRID:grid.89957.3a)
9 Geneseeq-Nanjing Technology Inc., Nanjing, P.R. China (GRID:grid.89957.3a)
10 Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Department of Thoracic Surgery, Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Nanjing, P.R. China (GRID:grid.452509.f) (ISNI:0000 0004 1764 4566); Nanjing Medical University, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, P.R. China (GRID:grid.89957.3a) (ISNI:0000 0000 9255 8984)
11 Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Department of Thoracic Surgery, Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Nanjing, P.R. China (GRID:grid.452509.f) (ISNI:0000 0004 1764 4566); Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Department of Science and Technology, Nanjing, P.R. China (GRID:grid.452509.f) (ISNI:0000 0004 1764 4566); Jiangsu Biobank of Clinical Resources, Biobank of Lung Cancer, Nanjing, P.R. China (GRID:grid.452509.f); Nanjing Medical University, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, P.R. China (GRID:grid.89957.3a) (ISNI:0000 0000 9255 8984)




